News
Media
Conferences
Events
Partners
Publications
Resources
Biomarker Consortium
Subscribe

Your AI-Trained Oncology Knowledge Connection!

Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology

Articles by Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology

Bradley J. Monk, MD, FACS, FACOG

Dr. Monk on Potential Shifts to Treatment Sequencing Strategies in Cervical Cancer

ByBradley J. Monk, MD, FACS, FACOG, Arizona Oncology

October 29th 2021

Bradley J. Monk, MD, FACS, FACOG, discusses potential shifts to treatment sequencing strategies in cervical cancer.

Bradley J. Monk, MD, FACS, FACOG

Dr. Monk on the Utility of PARP Inhibitors as Frontline Maintenance in Ovarian Cancer

ByBradley J. Monk, MD, FACS, FACOG, Arizona Oncology

August 19th 2021

Bradley J. Monk, MD, FACS, FACOG, discusses the utility of PARP inhibitors as frontline maintenance therapy in ovarian cancer.

Bradley J. Monk, MD, FACS, FACOG, of Arizona Oncology

Dr. Monk on the Utility of PARP Inhibitors as Maintenance Therapy in Ovarian Cancer

ByBradley J. Monk, MD, FACS, FACOG, Arizona Oncology,Bradley J. Monk, MD, FACOG, FACS

July 28th 2021

Bradley J. Monk, MD, FACS, FACOG, discusses the utility of PARP inhibitors as maintenance therapy in ovarian cancer.

Managing AEs With Pembrolizumab and Lenvatinib

ByBradley J. Monk, MD, FACS, FACOG, Arizona Oncology,Nicoletta Colombo, MD, PhD,Vicky Makker, MD, Memorial Sloan Kettering Cancer Center,Domenica Lorusso, MD, PhD,David M. O'Malley, MD, The Ohio State University

June 1st 2021

Key opinion leaders emphasize the importance of the management of adverse events in using pembrolizumab and lenvatinib.

Experience in Using Pembrolizumab + Lenvatinib in Advanced Endometrial Cancer

ByBradley J. Monk, MD, FACS, FACOG, Arizona Oncology,Nicoletta Colombo, MD, PhD,Vicky Makker, MD, Memorial Sloan Kettering Cancer Center,Domenica Lorusso, MD, PhD,David M. O'Malley, MD, The Ohio State University

June 1st 2021

Experts give insight on their clinical use of pembrolizumab-lenvatinib. They highlight dose adjustments and the importance of the increased knowledge of adverse events.

A Discussion on the Study 309/KEYNOTE-775 Data

ByBradley J. Monk, MD, FACS, FACOG, Arizona Oncology,Nicoletta Colombo, MD, PhD,Vicky Makker, MD, Memorial Sloan Kettering Cancer Center,Domenica Lorusso, MD, PhD,David M. O'Malley, MD, The Ohio State University

May 25th 2021

Key opinion leaders discuss the presented data from Study 309/KEYNOTE-775, highlighting patient reported outcomes, safety, and dosing.

Results from Study 309/KEYNOTE-775

ByBradley J. Monk, MD, FACS, FACOG, Arizona Oncology,Nicoletta Colombo, MD, PhD,Vicky Makker, MD, Memorial Sloan Kettering Cancer Center,Domenica Lorusso, MD, PhD,David M. O'Malley, MD, The Ohio State University

May 25th 2021

Vicky Makker, MD, presents the results from Study 309/KEYNOTE-775, as well as key safety findings.

Bradley J. Monk, MD, FACS, FACOG

Dr. Monk on Guidelines for Maintenance PARP Inhibitors in Ovarian Cancer

ByBradley J. Monk, MD, FACS, FACOG, Arizona Oncology

May 19th 2021

Bradley J. Monk, MD, FACS, FACOG, highlights current guidelines for utilizing maintenance PARP inhibitors in the treatment of patients with ovarian cancer.

Study 309/KEYNOTE-775 Trial Design

ByBradley J. Monk, MD, FACS, FACOG, Arizona Oncology,Nicoletta Colombo, MD, PhD,Vicky Makker, MD, Memorial Sloan Kettering Cancer Center,Domenica Lorusso, MD, PhD,David M. O'Malley, MD, The Ohio State University

May 18th 2021

Vicky Makker, MD, walks through the trial design of Study 309/KEYNOTE-775.

Therapeutic Approaches in Endometrial Cancer

ByBradley J. Monk, MD, FACS, FACOG, Arizona Oncology,Nicoletta Colombo, MD, PhD,Vicky Makker, MD, Memorial Sloan Kettering Cancer Center,Domenica Lorusso, MD, PhD,David M. O'Malley, MD, The Ohio State University

May 18th 2021

Experts review optimal approaches to treatment in advanced endometrial cancer, touching on clinical trial data.

Bradley J. Monk, MD, FACS, FACOG, of Arizona Oncology

Dr. Monk on the Clinical Implications of the PRIMA Trial in Advanced Ovarian Cancer

ByBradley J. Monk, MD, FACS, FACOG, Arizona Oncology

April 29th 2021

Bradley J. Monk, MD, FACS, FACOG, discusses the clinical implications of the phase 3 PRIMA trial in newly diagnosed advanced ovarian cancer.

Future of Advanced Endometrial Cancer

ByBradley J. Monk, MD, FACS, FACOG, Arizona Oncology,Kathleen N. Moore, MD, MS, University of Oklahoma,David M. O'Malley, MD, The Ohio State University,Brian M. Slomovitz, MD, Florida International University,Krishnansu S. Tewari, MD, University of California, Irvine

January 4th 2021

Novel Targets for Advanced Endometrial Cancer

ByBradley J. Monk, MD, FACS, FACOG, Arizona Oncology,Kathleen N. Moore, MD, MS, University of Oklahoma,David M. O'Malley, MD, The Ohio State University,Brian M. Slomovitz, MD, Florida International University,Krishnansu S. Tewari, MD, University of California, Irvine

January 4th 2021

Endometrial Cancer: Chemo-Free Regimens on the Horizon

ByBradley J. Monk, MD, FACS, FACOG, Arizona Oncology,Kathleen N. Moore, MD, MS, University of Oklahoma,David M. O'Malley, MD, The Ohio State University,Brian M. Slomovitz, MD, Florida International University,Krishnansu S. Tewari, MD, University of California, Irvine

January 4th 2021

Emerging Agents: Treatment of Endometrial Cancer

ByBradley J. Monk, MD, FACS, FACOG, Arizona Oncology,Kathleen N. Moore, MD, MS, University of Oklahoma,David M. O'Malley, MD, The Ohio State University,Brian M. Slomovitz, MD, Florida International University,Krishnansu S. Tewari, MD, University of California, Irvine

January 4th 2021

Sequencing for Advanced Endometrial Cancer

ByBradley J. Monk, MD, FACS, FACOG, Arizona Oncology,Kathleen N. Moore, MD, MS, University of Oklahoma,David M. O'Malley, MD, The Ohio State University,Brian M. Slomovitz, MD, Florida International University,Krishnansu S. Tewari, MD, University of California, Irvine

January 4th 2021

Recurrent Endometrial Cancer: Safety of Combination Therapy

ByBradley J. Monk, MD, FACS, FACOG, Arizona Oncology,Kathleen N. Moore, MD, MS, University of Oklahoma,David M. O'Malley, MD, The Ohio State University,Brian M. Slomovitz, MD, Florida International University,Krishnansu S. Tewari, MD, University of California, Irvine

January 4th 2021

Combination Therapy for Recurrent Endometrial Cancer

ByBradley J. Monk, MD, FACS, FACOG, Arizona Oncology,Kathleen N. Moore, MD, MS, University of Oklahoma,David M. O'Malley, MD, The Ohio State University,Brian M. Slomovitz, MD, Florida International University,Krishnansu S. Tewari, MD, University of California, Irvine

January 4th 2021

Emerging ICI Therapy for Advanced Endometrial Cancer

ByBradley J. Monk, MD, FACS, FACOG, Arizona Oncology,Kathleen N. Moore, MD, MS, University of Oklahoma,David M. O'Malley, MD, The Ohio State University,Brian M. Slomovitz, MD, Florida International University,Krishnansu S. Tewari, MD, University of California, Irvine

January 4th 2021

Immune Checkpoint Inhibitors in Advanced Endometrial Cancer

ByBradley J. Monk, MD, FACS, FACOG, Arizona Oncology,Kathleen N. Moore, MD, MS, University of Oklahoma,David M. O'Malley, MD, The Ohio State University,Brian M. Slomovitz, MD, Florida International University,Krishnansu S. Tewari, MD, University of California, Irvine

January 4th 2021

GOG-258 and PORTEC-3 Studies in Endometrial Cancer

ByBradley J. Monk, MD, FACS, FACOG, Arizona Oncology,Kathleen N. Moore, MD, MS, University of Oklahoma,David M. O'Malley, MD, The Ohio State University,Brian M. Slomovitz, MD, Florida International University,Krishnansu S. Tewari, MD, University of California, Irvine

January 4th 2021

GOG-249 Study in Early-Stage Endometrial Cancer

ByBradley J. Monk, MD, FACS, FACOG, Arizona Oncology,Kathleen N. Moore, MD, MS, University of Oklahoma,David M. O'Malley, MD, The Ohio State University,Brian M. Slomovitz, MD, Florida International University,Krishnansu S. Tewari, MD, University of California, Irvine

January 4th 2021

GOG 0209 Study in Advanced Endometrial Cancer

ByBradley J. Monk, MD, FACS, FACOG, Arizona Oncology,Kathleen N. Moore, MD, MS, University of Oklahoma,David M. O'Malley, MD, The Ohio State University,Brian M. Slomovitz, MD, Florida International University,Krishnansu S. Tewari, MD, University of California, Irvine

January 4th 2021

Role of Biomarker Testing in Endometrial Cancer

ByBradley J. Monk, MD, FACS, FACOG, Arizona Oncology,Kathleen N. Moore, MD, MS, University of Oklahoma,David M. O'Malley, MD, The Ohio State University,Brian M. Slomovitz, MD, Florida International University,Krishnansu S. Tewari, MD, University of California, Irvine

January 4th 2021

Risk Classification of Endometrial Cancer

ByBradley J. Monk, MD, FACS, FACOG, Arizona Oncology,Kathleen N. Moore, MD, MS, University of Oklahoma,David M. O'Malley, MD, The Ohio State University,Brian M. Slomovitz, MD, Florida International University,Krishnansu S. Tewari, MD, University of California, Irvine

January 4th 2021

Overview of Endometrial Cancer

ByBradley J. Monk, MD, FACS, FACOG, Arizona Oncology,Kathleen N. Moore, MD, MS, University of Oklahoma,David M. O'Malley, MD, The Ohio State University,Brian M. Slomovitz, MD, Florida International University,Krishnansu S. Tewari, MD, University of California, Irvine

January 4th 2021

Rapid Readouts: Phase III PAOLA-1/ENGOT-ov25 Trial

ByBradley J. Monk, MD, FACS, FACOG, Arizona Oncology

August 24th 2020

Dr. Monk on Emerging Therapies in Cervical Cancer

ByBradley J. Monk, MD, FACS, FACOG, Arizona Oncology

August 11th 2020

Bradley J. Monk, MD, FACS, FACOG, discusses emerging therapies in cervical cancer.

Dr. Monk on the Importance of Early Pap Testing in Cervical Cancer

ByBradley J. Monk, MD, FACS, FACOG, Arizona Oncology

July 27th 2020

Bradley J. Monk, MD, FACS, FACOG, discusses the importance of Pap testing early on in cervical cancer.

Dr. Monk on the Limitations of Current Treatment in Metastatic/Recurrent Cervical Cancer

ByBradley J. Monk, MD, FACS, FACOG, Arizona Oncology

July 24th 2020

Bradley J. Monk, MD, FACS, FACOG, discusses the limitations of current treatment options in metastatic or recurrent cervical cancer.

Latest Updated Articles

Study 309/KEYNOTE-775 Trial Design
Published: May 18th 2021 | Updated:
Managing AEs With Pembrolizumab and Lenvatinib
Published: June 1st 2021 | Updated:
Rapid Readouts: Phase III PAOLA-1/ENGOT-ov25 Trial
Published: August 24th 2020 | Updated:
A Discussion on the Study 309/KEYNOTE-775 Data
Published: May 25th 2021 | Updated:
Therapeutic Approaches in Endometrial Cancer
Published: May 18th 2021 | Updated:
Results from Study 309/KEYNOTE-775
Published: May 25th 2021 | Updated:

Trending on OncLive

FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma

PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer

Dr Braunstein on the FDA Approval of Subcutaneous Daratumumab With VRd For Newly Diagnosed Multiple Myeloma

Ixazomib-Containing Combinations Signal Potential for More PI-Based Regimens in R/R Multiple Myeloma

Meta-Analysis Characterizes Nivolumab/Ipilimumab Hyperprogression in Renal Medullary Carcinoma